1717 K Street NW, Suite 900

Washington, DC 20006-5349

(877) 363-6376

HELPLINE

NEWS

What happens when we combine chemotherapy with immunotherapy for mesothelioma?

chemotherapy with immunotherapy

Separately, chemotherapy and immunotherapy are both approved to treat mesothelioma, and individually they work equally well for those patients with the epithelioid type of disease. Currently, the question in front of scientists is what happens when those two treatments are combined?

DREAMER, a new clinical trial enrolling right now in the United States and Australia, is looking to find those answers. In this episode of MesoTV we talk with one of the principal investigators of this study, Dr. Patrick Forde of Johns Hopkins, to ask him about what this trial means to patients. If a patients is considering enrolling in this trial, they should watch this episode. The interview is moderated by Shannon Sinclair, RN, BSN, OCN, the oncology nurse at the Mesothelioma Applied Research Foundation. www.curemeso.org

Our Sponsors

MesoTV is a program by the Mesothelioma Applied Research Foundation. This program is made possible by our generous sponsors: Maune Raichle Hartley French & Mudd, LLC (MRHFM); Bristol Myers Squibb; Novocure, Merck, The Gori Law Firm, TCR2, AstraZeneca, Early Lucarelli Sweeney & Meisenkothen.

Search our previous episodes for topics/speakers of interest to you at www.curemeso.org/mesotv.

Also...

In Other News

Survivorship Panel

Many mesothelioma patients beat their odds and go on to live rich, fulfilling lives. This panel has three long term patients who discuss the issues

Read More »

Share:

Facebook
Twitter
LinkedIn